Obecabtagene autoleucel clinical trials
Also written AUTO1.
How each study uses obecabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the obecabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 Nov 2024 · Aucatzyl · BLA 125813 (FDA, Purple Book)
- European Union
- 17 Jul 2025 · Aucatzyl · EMEA/H/C/005907 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Autolus Limited (5) · Memorial Sloan Kettering Cancer Center (1) · M.D. Anderson Cancer Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test obecabtagene autoleucel.
- Sep 2027Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusPhase 1 · Autolus Limited
- Nov 2027A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)Phase 1 · Autolus Limited
Studies
Open first, then newest update. How each study uses obecabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)RecruitingPhase 2Autolus LimitedNCT07053800Written as Obecabtagene autoleucel
- Obe-cel in Refractory Progressive Forms of Multiple SclerosisRecruitingPhase 1Autolus LimitedNCT07139743Written as Obecabtagene autoleucel (obe-cel)
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingPhase 1Autolus LimitedNCT06173518Written as AUTO1
- A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07400029Written as Obecabtagene Autoleucel
- Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)RecruitingPhase 2M.D. Anderson Cancer CenterNCT07053059Written as Obecabtagene autoleucel
- Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusActive, not recruitingPhase 1Autolus LimitedNCT06333483Written as Obecabtagene autoleucel (obe-cel)
- A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Active, not recruitingPhase 1/2Autolus LimitedNCT04404660Written as AUTO1
Codes
What other systems call obecabtagene autoleucel · ClinicalTrials.gg INT015407
- UNII (FDA) 760HJB0YRDOBECABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C172746Obecabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 760HJB0YRD | OBECABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C172746 | Obecabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.